Targeted drug delivery:
Gespeichert in:
| Weitere Verfasser: | |
|---|---|
| Format: | Buch |
| Sprache: | English |
| Veröffentlicht: |
Weinheim
Wiley-VCH
[2023]
|
| Schriftenreihe: | Methods and principles in medicinal chemistry
Volume 82 |
| Schlagworte: | |
| Online-Zugang: | Kurzbeschreibung Inhaltsverzeichnis |
| Beschreibung: | xvii, 438 Seiten Illustrationen, Diagramme 24.4 cm x 17 cm |
| ISBN: | 9783527347810 352734781X |
Internformat
MARC
| LEADER | 00000nam a2200000 cb4500 | ||
|---|---|---|---|
| 001 | BV048641353 | ||
| 003 | DE-604 | ||
| 005 | 20240311 | ||
| 007 | t | ||
| 008 | 230110s2023 gw a||| |||| 00||| eng d | ||
| 015 | |a 22,N15 |2 dnb | ||
| 016 | 7 | |a 1255089520 |2 DE-101 | |
| 020 | |a 9783527347810 |9 978-3-527-34781-0 | ||
| 020 | |a 352734781X |9 3-527-34781-X | ||
| 024 | 3 | |a 9783527347810 | |
| 035 | |a (OCoLC)1357148901 | ||
| 035 | |a (DE-599)DNB1255089520 | ||
| 040 | |a DE-604 |b ger |e rda | ||
| 041 | 0 | |a eng | |
| 044 | |a gw |c XA-DE-BW | ||
| 049 | |a DE-29T |a DE-19 |a DE-703 |a DE-11 | ||
| 084 | |a VX 8560 |0 (DE-625)147831:253 |2 rvk | ||
| 084 | |8 1\p |a 540 |2 23sdnb | ||
| 245 | 1 | 0 | |a Targeted drug delivery |c edited by Yogeshwar Bachhav |
| 264 | 1 | |a Weinheim |b Wiley-VCH |c [2023] | |
| 264 | 4 | |c © 2023 | |
| 300 | |a xvii, 438 Seiten |b Illustrationen, Diagramme |c 24.4 cm x 17 cm | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 1 | |a Methods and principles in medicinal chemistry |v Volume 82 | |
| 650 | 0 | 7 | |a Targeted drug delivery |0 (DE-588)4302415-4 |2 gnd |9 rswk-swf |
| 653 | |a CH62: Wirkstoffformulierung, Wirkstofftransport | ||
| 653 | |a Chemie | ||
| 653 | |a Chemistry | ||
| 653 | |a Drug Formulation & Delivery | ||
| 653 | |a MDM0: Pharmakologie u. Pharmazeutische Medizin | ||
| 653 | |a Medical Science | ||
| 653 | |a Medizin | ||
| 653 | |a NT40: Nanomedizin | ||
| 653 | |a Nanomedicine | ||
| 653 | |a Nanomedizin | ||
| 653 | |a Nanotechnologie | ||
| 653 | |a Nanotechnology | ||
| 653 | |a Pharmacology & Pharmaceutical Medicine | ||
| 653 | |a Pharmakologie | ||
| 653 | |a Pharmakologie u. Pharmazeutische Medizin | ||
| 653 | |a Wirkstoffformulierung, Wirkstofftransport | ||
| 653 | |a Wirkstofffreisetzung | ||
| 655 | 7 | |0 (DE-588)4143413-4 |a Aufsatzsammlung |2 gnd-content | |
| 689 | 0 | 0 | |a Targeted drug delivery |0 (DE-588)4302415-4 |D s |
| 689 | 0 | |5 DE-604 | |
| 700 | 1 | |a Bachhav, Yogeshwar G. |0 (DE-588)1198937505 |4 edt | |
| 710 | 2 | |a Wiley-VCH |0 (DE-588)16179388-5 |4 pbl | |
| 776 | 0 | 8 | |i Erscheint auch als |n Online-Ausgabe, PDF |z 978-3-527-82786-2 |
| 776 | 0 | 8 | |i Erscheint auch als |n Online-Ausgabe, EPUB |z 978-3-527-82787-9 |
| 776 | 0 | 8 | |i Erscheint auch als |n Online-Ausgabe, oBook |z 978-3-527-82785-5 |
| 830 | 0 | |a Methods and principles in medicinal chemistry |v Volume 82 |w (DE-604)BV035418617 |9 82 | |
| 856 | 4 | 2 | |m X:MVB |u http://www.wiley-vch.de/publish/dt/books/ISBN978-3-527-34781-0/ |3 Kurzbeschreibung |
| 856 | 4 | 2 | |m DNB Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=034016275&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-034016275 | ||
| 883 | 1 | |8 1\p |a vlb |d 20220408 |q DE-101 |u https://d-nb.info/provenance/plan#vlb | |
Datensatz im Suchindex
| _version_ | 1804184783960408064 |
|---|---|
| adam_text | V
CONTENTS
A
PERSONAL
FOREWORD
XIII
PREFACE
XV
1
BASICS
OF
TARGETED
DRUG
DELIVERY
1
KSHAMA
A.
DOSHI
1.1
1.1.1
1.2
1.3
1.3.1
1.3.1.1
1.3.1.2
1.3.1.3
1.3.2
1.3.3
1.3.3.1
1.3.3.2
1.4
1.4.1
1.4.2
1.4.3
1.4.4
1.4.5
1.5
1.6
1.6.1
1.6.2
1.7
1.8
1.9
INTRODUCTION
1
CONCEPT
OF
BIOAVAILABILITY
AND
THERAPEUTIC
INDEX
2
TARGETED
DRUG
DELIVERY
2
STRATEGIES
FOR
DRUG
TARGETING
3
PASSIVE
TARGETING
4
RETICULOENDOTHELIAL
SYSTEM
(RES)
SYSTEM
4
ENHANCED
PERMEABILITY
AND
RETENTION
(EPR)
EFFECT
4
LOCALIZED
DELIVERY
4
ACTIVE
TARGETING
5
PHYSICAL
TARGETING
5
ULTRASOUND
FOR
TARGETING
6
MAGNETIC
FIELD
FOR
TARGETING
6
THERAPEUTIC
APPLICATIONS
OF
TARGETED
DRUG
DELIVERY
6
DIABETES
MANAGEMENT
6
NEUROLOGICAL
DISEASES
7
CARDIOVASCULAR
DISEASES
8
RESPIRATORY
DISEASES
9
CANCER
INDICATIONS
9
TARGETED
DUG-DELIVERY
PRODUCTS
10
CHALLENGES
11
PASSIVE
TARGETING
AND
EPR
EFFECT
12
ACTIVE
TARGETING
12
SCALE-UP
AND
CHALLENGES
13
CURRENT
STATUS
14
CONCLUSION
AND
PROSPECTS
15
REFERENCES
16
VI
CONTENTS
2
ADDRESSING
UNMET
MEDICAL
NEEDS
USING
TARGETED
DRUG-DELIVERY
SYSTEMS:
EMPHASIS
ON
NANOMEDICINE-BASED
APPLICATIONS
21
CHANDRAKANTSING
PORDESHI,
RAJU
SONAWANE,
AND
YOGESHWAR
BACHHAV
2.1
2.2
2.2.1
2.2.1.1
2.2.1.2
2.2.13
2.2.1.4
2.2.1.5
2.2.2
2.2.2.1
2.2.2.2
2.3
2.4
INTRODUCTION
21
TARGETED
DRUG-DELIVERY
SYSTEMS
FOR
UNMET
MEDICAL
NEEDS
23
TARGETING
LIGANDS
25
SMALL
MOLECULES
AS
TARGETING
LIGANDS
25
APTAMERS
AS
TARGETING
LIGANDS
27
ANTIBODIES
AS
TARGETING
LIGANDS
28
LECTINS
AS
TARGETING
LIGANDS
28
LACTOFERRINS
AS
TARGETING
LIGANDS
29
TARGETING
APPROACHES
29
DISEASE-BASED
TARGETING
29
LOCATION-BASED
TARGETING
32
REGULATORY
ASPECTS
AND
CLINICAL
PERSPECTIVES
35
CONCLUSION
AND
FUTURE
OUTLOOK
38
LIST
OF
ABBREVIATIONS
38
REFERENCES
39
3
NANOCARRIERS-BASED
TARGETED
DRUG
DELIVERY
SYSTEMS:
SMALL
AND
MACROMOLECULES
45
PRESHITA
DESAI
3.1
NANOCARRIERS
(NANOMEDICINE)
-
OVERVIEW
AND
ROLE
IN
TARGETED
DRUG
DELIVERY
45
3.2
3.2.1
3.3
3.4
3.4.1
3.4.2
3.4.3
3.4.4
3.4.5
3.4.6
3.5
PASSIVE
TARGETING
APPROACHES
50
ENHANCED
PERMEABILITY
AND
RETENTION-EFFECT-BASED
TARGETING
50
ACTIVE
TARGETING
APPROACHES
52
STIMULI
RESPONSIVE TARGETED
NCS
54
REDOX
STIMULI
RESPONSIVE
TARGETED
NCS
55
PH
STIMULI
RESPONSIVE
TARGETED
NCS
56
ENZYME
STIMULI
RESPONSIVE
TARGETED
NCS
57
TEMPERATURE
STIMULI
RESPONSIVE
TARGETED
NCS
58
ULTRASOUND
STIMULI
RESPONSIVE
TARGETED
NCS
59
MAGNETIC
FIELD
STIMULI
RESPONSIVE
TARGETED
NCS
59
CONCLUSION
AND
FUTURE
PROSPECTS
60
REFERENCES
60
4
LIPOSOMES
AS
TARGETED
DRUG-DELIVERY
SYSTEMS
69
RAGHAVENDRA
C.
MUNDARGI,
NEETIKA
TANEJA,
JAYESHKUMAR
J.
HADIA,
AND
AJAY
J.
KHOPADE
4.1
4.2
4.3
INTRODUCTION
69
LIPOSOME
COMMERCIAL
LANDSCAPE
72
IMPORTANT
CONSIDERATIONS
IN
DEVELOPMENT
AND
CHARACTERIZATION
OF
LIPOSOMES
80
CONTENTS
VII
4.3.1
4.3.2
4.3.3
4.3.4
4.3.5
4.3.6
4.3.7
4.3.8
4.4
4.4.1
4.4.2
4.4.2.1
4.4.2.2
4.5
SELECTION
OF
LIPIDS
80
DRUG
:
LIPID
RATIO
81
PEGYLATION
82
LIGAND
ANCHORING
83
DRUG-LOADING
TECHNIQUES
84
PHYSICOCHEMICAL
CHARACTERIZATION
85
MANUFACTURING
PROCESS
86
PRODUCT
STABILITY
87
TARGETED
DELIVERY
OF
LIPOSOMES
88
PASSIVE
TARGETING
89
ACTIVE-TARGETED
DELIVERY
92
CANCER
CELL
TARGETING
94
TUMOR
ENDOTHELIUM
TARGETING
98
RECENT
CLINICAL
TRIALS
WITH
LIPOSOMES
WITH
INVESTIGATIONAL
LIPOSOME
CANDIDATES
102
4.6
FACTORS
INFLUENCING
THE
CLINICAL
TRANSLATION
OF
LIPOSOMES
FOR
TARGETED
DELIVERY
103
4.7
CONCLUSIONS
AND
FUTURE
OF
PROSPECTS
OF
TARGETED
LIPOSOMAL-DELIVERY
SYSTEMS
108
LIST
OF
ABBREVIATIONS
110
REFERENCES
112
5
ANTIBODY-DRUG
CONJUGATES:
DEVELOPMENT
AND
APPLICATIONS
127
RAJESH
PRADHAN,
MEGHNA
PANDEY,
SIDDHANTH
HEJMADY,
RAJEEV
TALIYAN,
GAUTAM
SINGHVI,
SUNIL
K.
DUBEY,
AND
SACHIN
DUBEY
5.1
5.2
5.2.1
5.2.2
5.2.3
5.3
5.4
5.4.1
5.4.2
5.4.3
5.4.3.1
5.4.3.2
5.4.3.3
5.5
5.5.1
5.5.1.1
5.5.1.2
5.5.1.3
5.5.1.4
INTRODUCTION
127
DESIGN
OF
ADCS
128
ANTIBODY
129
LINKER
130
PAYLOAD
132
MECHANISM
OF
ACTION
133
PHARMACOKINETIC
CONSIDERATIONS
FOR
ADCS
134
HETEROGENEITY
OF
ADCS
134
BIOANALYTICAL
CONSIDERATIONS
FOR
ADCS
135
PHARMACOKINETIC
PARAMETERS
OF
ADCS
136
ABSORPTION
136
DISTRIBUTION
136
METABOLISM
AND
ELIMINATION
136
APPLICATIONS
OF
ADCS
137
APPROVED
ADCS
IN
THE
MARKET
137
GEMTUZUMAB
OZOGAMICIN
137
BRENTUXIMAB
VEDOTIN
139
ADO-TRASTUZUMAB
EMTANSINE
(T-DM1)
139
INOTUZUMAB
OZOGAMICIN
139
VIII
I
CONTENTS
5.5.1.5
5.5.1.6
5.5.1.7
5.5.2
5.5.3
5.5.4
5.6
5.7
5.7.1
5.7.2
5.8
POLATUZUMAB
VEDOTIN-PIIQ
140
ENFORTUMAB
VEDOTIN
140
TRASTUZUMAB
DERUXTECAN
140
USE
OF
ADCS
IN
RHEUMATOID
ARTHRITIS
141
USE
OF
ADCS
IN
BACTERIAL
INFECTIONS
141
USE
OF
ADCS
IN
OPHTHALMOLOGY
141
RESISTANCE
OF
ADC
142
REGULATORY
ASPECTS
FOR
ADCS
143
ROLEOFONDQA
143
ROLEOFOBP
144
CONCLUSION
AND
FUTURE
DIRECTION
144
REFERENCES
145
6
GENE-DIRECTED
ENZYME-PRODRUG
THERAPY
(GDEPT)
AS
A
SUICIDE
GENE
THERAPY
MODALITY
FOR
CANCER
TREATMENT
155
PRASHANT
S.
KHARKAR
AND
ATUL
L.
JADHAV
6.1
6.2
6.2.1
6.2.2
6.2.3
6.3
6.4
INTRODUCTION
155
GDEPT
FOR
DIFFICULT-TO-TREAT
CANCERS
159
HIGH
GRADE
GLIOMAS
(HGGS)
159
TRIPLE-NEGATIVE
BREAST
CANCER
(TNBC)
161
OTHER
CANCERS
162
NOVEL
ENZYMES
FOR
GDEPT
164
CONCLUSIONS
165
REFERENCES
165
7
TARGETED
PRODRUGS
IN
ORAL
DRUG
DELIVERY
169
MILICA
MARKOVIC,
SHIMON
BEN-SHABAT,
AND
ARIK
DAHAN
7.1
7.1.1
7.2
7.2.1
7.2.1.1
7.2.1.2
7.2.1.3
INTRODUCTION
169
CLASSIC
VS.
MODERN
PRODRUG
APPROACH
170
MODERN,
TARGETED
PRODRUG
APPROACH
171
PRODRUG
APPROACH-TARGETING
ENZYMES
171
VALACYCLOVIRASE-MEDIATED
PRODRUG
ACTIVATION
172
PHOSPHOLIPASE
A
2
-MEDIATED
PRODRUG
ACTIVATION
173
ANTIBODY,
GENE,
AND
VIRUS-DIRECTED
ENZYME-PRODRUG
THERAPY
175
7.2.2
7.2.2.1
7.2.2.2
7.2.2.3
7.3
7.4
7.5
7.6
PRODRUG
APPROACH
TARGETING
TRANSPORTERS
176
PEPTIDE
TRANSPORTER
1
177
MONOCARBOXYLATE
TRANSPORTER
TYPE
1
179
BILE
ACID
TRANSPORTERS
180
COMPUTATIONAL
APPROACHES
IN
TARGETED
PRODRUG
DESIGN
181
DISCUSSION
182
FUTURE
PROSPECTS
AND
CLINICAL
APPLICATIONS
183
CONCLUSION
183
REFERENCES
184
CONTENTS
IX
8
EXOSOMES
FOR
DRUG
DELIVERY
APPLICATIONS
IN
CANCER
AND
CARDIAC
INDICATIONS
193
ANJALI
PANDYA,
SREERANJINI
PULAKKAT,
AND
VANDANA
PATRAVALE
8.1
8.1.1
8.1.2
8.1.2.1
8.1.2.2
8.2
8.2.1
8.2.2
8.2.2.1
8.2.2.2
8.2.2.3
8.3
8.3.1
8.3.2
8.4
8.5
EXTRACELLULAR
VESICLES:
AN
OVERVIEW
193
EVOLUTION
OF
EXOSOMES
194
EXOSOMES
AS
DELIVERY
VEHICLES
FOR
THERAPEUTICS
195
ENDOGENOUS
LOADING
METHODS
198
EXOGENOUS
LOADING
METHODS
198
EXOSOMES
AS
CANCER
THERAPEUTICS
199
INFLUENCE
OF
DONOR
CELLS
202
DIFFERENT
THERAPEUTIC
CARGO
EXPLORED
IN
CANCER
THERAPY
202
DELIVERY
OF
PROTEINS
AND
PEPTIDES
203
DELIVERY
OF
CHEMOTHERAPEUTIC
CARGO
204
DELIVERY
OF
RNA
204
EXOSOME
BASED
DRUG
DELIVERY
FOR
CARDIOVASCULAR
DISEASES
206
DELIVERY
OF
CARDIOPROTECTIVE
RNAS
207
EXOSOMES
MODIFIED
WITH
CARDIAC
TARGETING
PEPTIDES
208
CLINICAL
EVALUATIONS
AND
FUTURE
ASPECTS
210
CONCLUSION
211
ACKNOWLEDGMENTS
212
REFERENCES
212
9
DELIVERY
OF
NUCLEIC
ACIDS,
SUCH
AS
SIRNA
AND
MRNA,
USING
COMPLEX
FORMULATIONS
221
ANONYA
PATTNAIK,
SWARNAPARABHA
PANY
A.
S.
SANKET,
SUDIPTEE
DAS,
SANGHAMITRA
PATI,
AND
SANGRAM
K.
SAMAL
9.1
9.2
9.2.1
9.2.1.1
9.2.1.2
9.2.1.3
9.2.2
9.2.2.1
9.2.2.2
9.2.2.3
9.3
9.3.1
9.3.2
9.3.3
9.4
9.5
INTRODUCTION
221
NA-BASED
COMPLEX
DELIVERY
SYSTEM
228
CLASSICAL
NA-BASED
COMPLEX
DELIVERY
SYSTEM
229
POLYMER-BASED
NA-COMPLEX
DELIVERY
SYSTEM
229
LIPID-BASED
COMPLEX
NA
DELIVERY
SYSTEM
230
PEPTIDE-BASED
COMPLEX
NA
DELIVERY
SYSTEM
231
ADVANCED
NA-BASED
COMPLEX
DELIVERY
SYSTEMS
232
INORGANIC
AND
HYBRID
NPS
232
SELF-ASSEMBLED
NA
NANOSTRUCTURES
233
EXOSOMES
AND
NANOCELLS
233
APPLICATIONS
OF
NA
COMPLEX
DELIVERY
SYSTEMS
234
GENOME
EDITING
235
CANCER
THERAPY
237
PROTEIN
THERAPY
238
FUTURE
PROSPECTIVE
239
CONCLUSION
240
ACKNOWLEDGMENTS
240
REFERENCES
240
X
CONTENTS
10
APPLICATION
OF
PROTAC
TECHNOLOGY
IN
DRUG
DEVELOPMENT
247
PRASHANT
S.
KHARKAR
AND
ATUL
L.
JADHAV
10.1
10.2
10.3
10.3.1
10.3.2
10.3.3
10.3.4
10.4
10.5
INTRODUCTION
247
DESIGN
OF
PROTACS:
A
BRIEF
OVERVIEW
252
THERAPEUTIC
APPLICATIONS
OF
PROTACS
254
CANCER
255
NEURODEGENERATIVE
DISORDERS
261
IMMUNOLOGICAL
DISEASES
263
VIRAL
INFECTIONS
264
CHALLENGES
AND
LIMITATIONS
IN
THE
DEVELOPMENT
PROTACS
265
FUTURE
PERSPECTIVES
266
REFERENCES
266
11
METAL
COMPLEXES
AS
THE
MEANS
OR
THE
END
OF
TARGETED
DELIVERY
FOR
UNMET
NEEDS
271
TREVOR
W.
HAMBLEY
11.1
11.2
11.2.1
11.2.2
11.2.3
11.3
11.3.1
11.4
11.5
11.5.1
11.5.2
11.5.3
11.6
11.7
11.8
11.9
INTRODUCTION
271
CLASS
1:
CHAPERONES
272
CHAPERONES
THAT
PROTECT
DRUGS
273
DELIVERY
TO
THE
CELLS
OR
ENVIRONMENTS
TO
BE
TARGETED
275
RELEASE
FROM
THE
METAL
WHERE
AND
WHEN
REQUIRED
276
CLASS
2:
ACTIVE
METAL
COMPLEXES
276
TARGETED
PLATINUM
AGENTS
277
CLASS
3:
DUAL-THREAT
METAL
COMPLEXES
279
TARGETING
STRATEGIES:
THE
CHEMICAL
AND
PHYSICAL
ENVIRONMENT
280
HYPOXIA
281
PH-BASED
TARGETING
282
THE
EPR
EFFECT
283
TARGETING
STRATEGIES:
TRANSPORTERS
284
TARGETING
STRATEGIES:
ENZYME
ACTIVATION
286
OTHER
TARGETING
STRATEGIES
287
CONCLUSIONS
288
REFERENCES
289
12
FORMULATION
OF
PEPTIDES
FOR
TARGETED
DELIVERY
299
PANKTI
GANATRA,
KAREN
SAISWANI,
NIKITA
NAIR,
AVINASH
GUNJAL,
RATNESH
JAIN,
AND
PRAJAKTA
DANDEKAR
12.1
12.2
12.2.1
12.2.2
12.2.3
12.2.4
12.2.5
12.2.6
12.3
INTRODUCTION
299
PEPTIDES
USED
IN
CANCER
THERAPY
302
LUNG
CANCER
303
MELANOMA
304
PANCREATIC
CANCER
306
BRAIN
CANCER
307
BREAST
CANCER
309
LEUKEMIA
312
PEPTIDE-TARGETING
BASED
ON
SITE
OF
ACTION
315
CONTENTS
XI
12.3.1
12.3.2
12.3.3
12.3.4
12.4
TOPICAL
DELIVERY
OF
PEPTIDES
315
OCULAR
DELIVERY
OF
PEPTIDES
31
7
BRAIN
DELIVERY
OF
PEPTIDES
319
LUNG-TARGETED
DELIVERY
OF
PEPTIDES
321
CONCLUSION
AND
FUTURE
PROSPECTS
323
REFERENCES
324
13
ANTIBODY-BASED
TARGETED
T-CELL
THERAPIES
327
MANOJ
BANSODE,
KAUSHIK
DEB,
AND
SARMISTHA
DEB
13.1
13.2
13.3
13.4
13.5
13.6
13.7
13.8
13.9
13.10
13.11
13.12
13.13
13.14
13.15
INTRODUCTION
327
IMMUNE-DIRECTED CANCER
CELL
DEATH
328
IMMUNOTHERAPY
STRATEGIES
IN
CANCER
328
T-CELL
THERAPY
329
NATURALLY
OCCURRING
T
CELLS
329
GENETICALLY
MODIFIED
OCCURRING
T
CELLS
330
CLINICAL
IMPLICATION OF
T-CELL
AND
CAR-T-CELL
THERAPY:
330
ANTIBODY-INDUCED
T-CELL
THERAPY
332
A
BISPECIFIC
ANTIBODY
(BSABS)-INDUCED
T-CELL
THERAPY
332
FORMATS
OF
BSABS
335
TRIOMAB
ANTIBODIES
IN
T-CELL
THERAPY
335
BISPECIFIC
ANTIBODIES
IN
T-CELL
THERAPY
336
CLINICALLY
APPROVED
T-CELL-ACTIVATING
ANTIBODIES
337
PROSPECTS
337
CONCLUSION
339
REFERENCES
339
14
DEVICES
FOR
ACTIVE
TARGETED
DELIVERY:
A
WAY
TO
CONTROL
THE
RATE
AND
EXTENT
OF
DRUG
ADMINISTRATION
349
JONATHAN
FARO
BARROS,
PHEDRA
F.
SAHRAOUI,
YOGESHVOR
N.
KALIA,
AND
MARIA
LAPTEVA
14.1
14.2
14.2.1
14.2.2
14.2.3
14.2.4
14.2.4.1
14.2.4.2
14.2.4.3
14.3
14.3.1
14.3.1.1
14.3.1.2
14.3.1.3
14.3.2
INTRODUCTION
349
MACROFABRICATED
DEVICES
-
DRUG
INFUSION
PUMPS
351
PERISTALTIC
PUMPS
351
GAS-DRIVEN
PUMPS
352
OSMOTIC
PUMPS
353
INSULIN
PUMPS
354
DIABETES
AND
INSULIN
PRODUCT
DEVELOPMENT
354
OPEN-LOOP
INSULIN
DELIVERY
SYSTEMS
355
CLOSED-LOOP
INSULIN
DELIVERY
SYSTEMS
360
MICROFABRICATED
AND
NANOFABRICATED
DRUG
DELIVERY
DEVICES
364
MICROELECTROMECHANICAL
SYSTEMS
(MEMS)
364
MICROCHIP-BASED
MEMS
364
PUMP-BASED
MEMS
366
MEMS
-
EFFORTS
TO
CLOSE
THE
LOOP
368
NANOFABRICATED
DRUG
DELIVERY
DEVICES
369
XII
I
CONTENTS
INDEX
425
14.4
14.5
NONINVASIVE
ACTIVE
DRUG
DELIVERY
SYSTEMS:
IONTOPHORESIS
372
CONCLUSIONS
376
ACKNOWLEDGMENTS
377
LIST
OF
ABBREVIATIONS
377
REFERENCES
378
15
DRUG
DELIVERY
TO
THE
BRAIN:
TARGETING
TECHNOLOGIES
TO
DELIVER
THERAPEUTICS
TO
BRAIN
LESIONS
389
NISHIT
PATHAK,
SUNIL
K.
VIMAL,
CAO
HONGYI,
AND
SANJIB
BHATTACHARYA
15.1
15.2
15.2.1
15.2.2
15.3
15.3.1
15.3.1.1
15.3.2
15.3.2.1
15.3.3
15.3.3.1
15.3.4
15.3.4.1
15.3.4.2
15.3.5
15.4
15.4.1
15.4.2
15.4.3
15.4.4
15.4.5
15.5
15.6
INTRODUCTION
389
BRAIN
TUMOR
390
OBSTACLES
TO
BRAIN
TUMOR-TARGETED
DELIVERY
391
BRAIN-TUMOR-FOCUSED
NANO-DRUG
DELIVERY
393
NEURODEGENERATIVE
DISEASES
396
ALZHEIMER
S
DISEASE
(AD)
396
ALZHEIMER
S
DISEASE
FOCUSED
ON
DRUG
DELIVERY
396
PARKINSON
S
DISEASE
399
DRUG
DELIVERY
FOCUSSED
ON
PARKINSON
S
DRUG
DISEASE
399
CEREBROVASCULAR
DISEASE
400
DRUG
DELIVERY
FOR
CEREBROVASCULAR
DISEASE
400
INFLAMMATORY
DISEASES
(ID)
402
INFLAMMATORY
DISEASES (ID)
FOCUSED
ON
DRUG
DELIVERY
402
DRUG
DELIVERY
FOR
THE
TREATMENT
OF
NEURO-AIDS
403
DRUG
DELIVERY
FOR
MULTIPLE
SCLEROSIS
(MS)
403
DRUG
DELIVERY
FOR
CNS
DISORDERS
404
TAU
THERAPY
405
IMMUNOTHERAPY
407
GENE
IMMUNOTHERAPY
(GIT)
407
CHEMOTHERAPY
(CT)
408
PHOTOIMMUNOTHERAPY
(PIT)
408
FUTURE
PROSPECTS
410
CONCLUSIONS
410
LIST
OF
ABBREVIATIONS
411
REFERENCES
412
|
| adam_txt |
V
CONTENTS
A
PERSONAL
FOREWORD
XIII
PREFACE
XV
1
BASICS
OF
TARGETED
DRUG
DELIVERY
1
KSHAMA
A.
DOSHI
1.1
1.1.1
1.2
1.3
1.3.1
1.3.1.1
1.3.1.2
1.3.1.3
1.3.2
1.3.3
1.3.3.1
1.3.3.2
1.4
1.4.1
1.4.2
1.4.3
1.4.4
1.4.5
1.5
1.6
1.6.1
1.6.2
1.7
1.8
1.9
INTRODUCTION
1
CONCEPT
OF
BIOAVAILABILITY
AND
THERAPEUTIC
INDEX
2
TARGETED
DRUG
DELIVERY
2
STRATEGIES
FOR
DRUG
TARGETING
3
PASSIVE
TARGETING
4
RETICULOENDOTHELIAL
SYSTEM
(RES)
SYSTEM
4
ENHANCED
PERMEABILITY
AND
RETENTION
(EPR)
EFFECT
4
LOCALIZED
DELIVERY
4
ACTIVE
TARGETING
5
PHYSICAL
TARGETING
5
ULTRASOUND
FOR
TARGETING
6
MAGNETIC
FIELD
FOR
TARGETING
6
THERAPEUTIC
APPLICATIONS
OF
TARGETED
DRUG
DELIVERY
6
DIABETES
MANAGEMENT
6
NEUROLOGICAL
DISEASES
7
CARDIOVASCULAR
DISEASES
8
RESPIRATORY
DISEASES
9
CANCER
INDICATIONS
9
TARGETED
DUG-DELIVERY
PRODUCTS
10
CHALLENGES
11
PASSIVE
TARGETING
AND
EPR
EFFECT
12
ACTIVE
TARGETING
12
SCALE-UP
AND
CHALLENGES
13
CURRENT
STATUS
14
CONCLUSION
AND
PROSPECTS
15
REFERENCES
16
VI
CONTENTS
2
ADDRESSING
UNMET
MEDICAL
NEEDS
USING
TARGETED
DRUG-DELIVERY
SYSTEMS:
EMPHASIS
ON
NANOMEDICINE-BASED
APPLICATIONS
21
CHANDRAKANTSING
PORDESHI,
RAJU
SONAWANE,
AND
YOGESHWAR
BACHHAV
2.1
2.2
2.2.1
2.2.1.1
2.2.1.2
2.2.13
2.2.1.4
2.2.1.5
2.2.2
2.2.2.1
2.2.2.2
2.3
2.4
INTRODUCTION
21
TARGETED
DRUG-DELIVERY
SYSTEMS
FOR
UNMET
MEDICAL
NEEDS
23
TARGETING
LIGANDS
25
SMALL
MOLECULES
AS
TARGETING
LIGANDS
25
APTAMERS
AS
TARGETING
LIGANDS
27
ANTIBODIES
AS
TARGETING
LIGANDS
28
LECTINS
AS
TARGETING
LIGANDS
28
LACTOFERRINS
AS
TARGETING
LIGANDS
29
TARGETING
APPROACHES
29
DISEASE-BASED
TARGETING
29
LOCATION-BASED
TARGETING
32
REGULATORY
ASPECTS
AND
CLINICAL
PERSPECTIVES
35
CONCLUSION
AND
FUTURE
OUTLOOK
38
LIST
OF
ABBREVIATIONS
38
REFERENCES
39
3
NANOCARRIERS-BASED
TARGETED
DRUG
DELIVERY
SYSTEMS:
SMALL
AND
MACROMOLECULES
45
PRESHITA
DESAI
3.1
NANOCARRIERS
(NANOMEDICINE)
-
OVERVIEW
AND
ROLE
IN
TARGETED
DRUG
DELIVERY
45
3.2
3.2.1
3.3
3.4
3.4.1
3.4.2
3.4.3
3.4.4
3.4.5
3.4.6
3.5
PASSIVE
TARGETING
APPROACHES
50
ENHANCED
PERMEABILITY
AND
RETENTION-EFFECT-BASED
TARGETING
50
ACTIVE
TARGETING
APPROACHES
52
STIMULI
RESPONSIVE TARGETED
NCS
54
REDOX
STIMULI
RESPONSIVE
TARGETED
NCS
55
PH
STIMULI
RESPONSIVE
TARGETED
NCS
56
ENZYME
STIMULI
RESPONSIVE
TARGETED
NCS
57
TEMPERATURE
STIMULI
RESPONSIVE
TARGETED
NCS
58
ULTRASOUND
STIMULI
RESPONSIVE
TARGETED
NCS
59
MAGNETIC
FIELD
STIMULI
RESPONSIVE
TARGETED
NCS
59
CONCLUSION
AND
FUTURE
PROSPECTS
60
REFERENCES
60
4
LIPOSOMES
AS
TARGETED
DRUG-DELIVERY
SYSTEMS
69
RAGHAVENDRA
C.
MUNDARGI,
NEETIKA
TANEJA,
JAYESHKUMAR
J.
HADIA,
AND
AJAY
J.
KHOPADE
4.1
4.2
4.3
INTRODUCTION
69
LIPOSOME
COMMERCIAL
LANDSCAPE
72
IMPORTANT
CONSIDERATIONS
IN
DEVELOPMENT
AND
CHARACTERIZATION
OF
LIPOSOMES
80
CONTENTS
VII
4.3.1
4.3.2
4.3.3
4.3.4
4.3.5
4.3.6
4.3.7
4.3.8
4.4
4.4.1
4.4.2
4.4.2.1
4.4.2.2
4.5
SELECTION
OF
LIPIDS
80
DRUG
:
LIPID
RATIO
81
PEGYLATION
82
LIGAND
ANCHORING
83
DRUG-LOADING
TECHNIQUES
84
PHYSICOCHEMICAL
CHARACTERIZATION
85
MANUFACTURING
PROCESS
86
PRODUCT
STABILITY
87
TARGETED
DELIVERY
OF
LIPOSOMES
88
PASSIVE
TARGETING
89
ACTIVE-TARGETED
DELIVERY
92
CANCER
CELL
TARGETING
94
TUMOR
ENDOTHELIUM
TARGETING
98
RECENT
CLINICAL
TRIALS
WITH
LIPOSOMES
WITH
INVESTIGATIONAL
LIPOSOME
CANDIDATES
102
4.6
FACTORS
INFLUENCING
THE
CLINICAL
TRANSLATION
OF
LIPOSOMES
FOR
TARGETED
DELIVERY
103
4.7
CONCLUSIONS
AND
FUTURE
OF
PROSPECTS
OF
TARGETED
LIPOSOMAL-DELIVERY
SYSTEMS
108
LIST
OF
ABBREVIATIONS
110
REFERENCES
112
5
ANTIBODY-DRUG
CONJUGATES:
DEVELOPMENT
AND
APPLICATIONS
127
RAJESH
PRADHAN,
MEGHNA
PANDEY,
SIDDHANTH
HEJMADY,
RAJEEV
TALIYAN,
GAUTAM
SINGHVI,
SUNIL
K.
DUBEY,
AND
SACHIN
DUBEY
5.1
5.2
5.2.1
5.2.2
5.2.3
5.3
5.4
5.4.1
5.4.2
5.4.3
5.4.3.1
5.4.3.2
5.4.3.3
5.5
5.5.1
5.5.1.1
5.5.1.2
5.5.1.3
5.5.1.4
INTRODUCTION
127
DESIGN
OF
ADCS
128
ANTIBODY
129
LINKER
130
PAYLOAD
132
MECHANISM
OF
ACTION
133
PHARMACOKINETIC
CONSIDERATIONS
FOR
ADCS
134
HETEROGENEITY
OF
ADCS
134
BIOANALYTICAL
CONSIDERATIONS
FOR
ADCS
135
PHARMACOKINETIC
PARAMETERS
OF
ADCS
136
ABSORPTION
136
DISTRIBUTION
136
METABOLISM
AND
ELIMINATION
136
APPLICATIONS
OF
ADCS
137
APPROVED
ADCS
IN
THE
MARKET
137
GEMTUZUMAB
OZOGAMICIN
137
BRENTUXIMAB
VEDOTIN
139
ADO-TRASTUZUMAB
EMTANSINE
(T-DM1)
139
INOTUZUMAB
OZOGAMICIN
139
VIII
I
CONTENTS
5.5.1.5
5.5.1.6
5.5.1.7
5.5.2
5.5.3
5.5.4
5.6
5.7
5.7.1
5.7.2
5.8
POLATUZUMAB
VEDOTIN-PIIQ
140
ENFORTUMAB
VEDOTIN
140
TRASTUZUMAB
DERUXTECAN
140
USE
OF
ADCS
IN
RHEUMATOID
ARTHRITIS
141
USE
OF
ADCS
IN
BACTERIAL
INFECTIONS
141
USE
OF
ADCS
IN
OPHTHALMOLOGY
141
RESISTANCE
OF
ADC
142
REGULATORY
ASPECTS
FOR
ADCS
143
ROLEOFONDQA
143
ROLEOFOBP
144
CONCLUSION
AND
FUTURE
DIRECTION
144
REFERENCES
145
6
GENE-DIRECTED
ENZYME-PRODRUG
THERAPY
(GDEPT)
AS
A
SUICIDE
GENE
THERAPY
MODALITY
FOR
CANCER
TREATMENT
155
PRASHANT
S.
KHARKAR
AND
ATUL
L.
JADHAV
6.1
6.2
6.2.1
6.2.2
6.2.3
6.3
6.4
INTRODUCTION
155
GDEPT
FOR
DIFFICULT-TO-TREAT
CANCERS
159
HIGH
GRADE
GLIOMAS
(HGGS)
159
TRIPLE-NEGATIVE
BREAST
CANCER
(TNBC)
161
OTHER
CANCERS
162
NOVEL
ENZYMES
FOR
GDEPT
164
CONCLUSIONS
165
REFERENCES
165
7
TARGETED
PRODRUGS
IN
ORAL
DRUG
DELIVERY
169
MILICA
MARKOVIC,
SHIMON
BEN-SHABAT,
AND
ARIK
DAHAN
7.1
7.1.1
7.2
7.2.1
7.2.1.1
7.2.1.2
7.2.1.3
INTRODUCTION
169
CLASSIC
VS.
MODERN
PRODRUG
APPROACH
170
MODERN,
TARGETED
PRODRUG
APPROACH
171
PRODRUG
APPROACH-TARGETING
ENZYMES
171
VALACYCLOVIRASE-MEDIATED
PRODRUG
ACTIVATION
172
PHOSPHOLIPASE
A
2
-MEDIATED
PRODRUG
ACTIVATION
173
ANTIBODY,
GENE,
AND
VIRUS-DIRECTED
ENZYME-PRODRUG
THERAPY
175
7.2.2
7.2.2.1
7.2.2.2
7.2.2.3
7.3
7.4
7.5
7.6
PRODRUG
APPROACH
TARGETING
TRANSPORTERS
176
PEPTIDE
TRANSPORTER
1
177
MONOCARBOXYLATE
TRANSPORTER
TYPE
1
179
BILE
ACID
TRANSPORTERS
180
COMPUTATIONAL
APPROACHES
IN
TARGETED
PRODRUG
DESIGN
181
DISCUSSION
182
FUTURE
PROSPECTS
AND
CLINICAL
APPLICATIONS
183
CONCLUSION
183
REFERENCES
184
CONTENTS
IX
8
EXOSOMES
FOR
DRUG
DELIVERY
APPLICATIONS
IN
CANCER
AND
CARDIAC
INDICATIONS
193
ANJALI
PANDYA,
SREERANJINI
PULAKKAT,
AND
VANDANA
PATRAVALE
8.1
8.1.1
8.1.2
8.1.2.1
8.1.2.2
8.2
8.2.1
8.2.2
8.2.2.1
8.2.2.2
8.2.2.3
8.3
8.3.1
8.3.2
8.4
8.5
EXTRACELLULAR
VESICLES:
AN
OVERVIEW
193
EVOLUTION
OF
EXOSOMES
194
EXOSOMES
AS
DELIVERY
VEHICLES
FOR
THERAPEUTICS
195
ENDOGENOUS
LOADING
METHODS
198
EXOGENOUS
LOADING
METHODS
198
EXOSOMES
AS
CANCER
THERAPEUTICS
199
INFLUENCE
OF
DONOR
CELLS
202
DIFFERENT
THERAPEUTIC
CARGO
EXPLORED
IN
CANCER
THERAPY
202
DELIVERY
OF
PROTEINS
AND
PEPTIDES
203
DELIVERY
OF
CHEMOTHERAPEUTIC
CARGO
204
DELIVERY
OF
RNA
204
EXOSOME
BASED
DRUG
DELIVERY
FOR
CARDIOVASCULAR
DISEASES
206
DELIVERY
OF
CARDIOPROTECTIVE
RNAS
207
EXOSOMES
MODIFIED
WITH
CARDIAC
TARGETING
PEPTIDES
208
CLINICAL
EVALUATIONS
AND
FUTURE
ASPECTS
210
CONCLUSION
211
ACKNOWLEDGMENTS
212
REFERENCES
212
9
DELIVERY
OF
NUCLEIC
ACIDS,
SUCH
AS
SIRNA
AND
MRNA,
USING
COMPLEX
FORMULATIONS
221
ANONYA
PATTNAIK,
SWARNAPARABHA
PANY
A.
S.
SANKET,
SUDIPTEE
DAS,
SANGHAMITRA
PATI,
AND
SANGRAM
K.
SAMAL
9.1
9.2
9.2.1
9.2.1.1
9.2.1.2
9.2.1.3
9.2.2
9.2.2.1
9.2.2.2
9.2.2.3
9.3
9.3.1
9.3.2
9.3.3
9.4
9.5
INTRODUCTION
221
NA-BASED
COMPLEX
DELIVERY
SYSTEM
228
CLASSICAL
NA-BASED
COMPLEX
DELIVERY
SYSTEM
229
POLYMER-BASED
NA-COMPLEX
DELIVERY
SYSTEM
229
LIPID-BASED
COMPLEX
NA
DELIVERY
SYSTEM
230
PEPTIDE-BASED
COMPLEX
NA
DELIVERY
SYSTEM
231
ADVANCED
NA-BASED
COMPLEX
DELIVERY
SYSTEMS
232
INORGANIC
AND
HYBRID
NPS
232
SELF-ASSEMBLED
NA
NANOSTRUCTURES
233
EXOSOMES
AND
NANOCELLS
233
APPLICATIONS
OF
NA
COMPLEX
DELIVERY
SYSTEMS
234
GENOME
EDITING
235
CANCER
THERAPY
237
PROTEIN
THERAPY
238
FUTURE
PROSPECTIVE
239
CONCLUSION
240
ACKNOWLEDGMENTS
240
REFERENCES
240
X
CONTENTS
10
APPLICATION
OF
PROTAC
TECHNOLOGY
IN
DRUG
DEVELOPMENT
247
PRASHANT
S.
KHARKAR
AND
ATUL
L.
JADHAV
10.1
10.2
10.3
10.3.1
10.3.2
10.3.3
10.3.4
10.4
10.5
INTRODUCTION
247
DESIGN
OF
PROTACS:
A
BRIEF
OVERVIEW
252
THERAPEUTIC
APPLICATIONS
OF
PROTACS
254
CANCER
255
NEURODEGENERATIVE
DISORDERS
261
IMMUNOLOGICAL
DISEASES
263
VIRAL
INFECTIONS
264
CHALLENGES
AND
LIMITATIONS
IN
THE
DEVELOPMENT
PROTACS
265
FUTURE
PERSPECTIVES
266
REFERENCES
266
11
METAL
COMPLEXES
AS
THE
MEANS
OR
THE
END
OF
TARGETED
DELIVERY
FOR
UNMET
NEEDS
271
TREVOR
W.
HAMBLEY
11.1
11.2
11.2.1
11.2.2
11.2.3
11.3
11.3.1
11.4
11.5
11.5.1
11.5.2
11.5.3
11.6
11.7
11.8
11.9
INTRODUCTION
271
CLASS
1:
CHAPERONES
272
CHAPERONES
THAT
PROTECT
DRUGS
273
DELIVERY
TO
THE
CELLS
OR
ENVIRONMENTS
TO
BE
TARGETED
275
RELEASE
FROM
THE
METAL
WHERE
AND
WHEN
REQUIRED
276
CLASS
2:
ACTIVE
METAL
COMPLEXES
276
TARGETED
PLATINUM
AGENTS
277
CLASS
3:
DUAL-THREAT
METAL
COMPLEXES
279
TARGETING
STRATEGIES:
THE
CHEMICAL
AND
PHYSICAL
ENVIRONMENT
280
HYPOXIA
281
PH-BASED
TARGETING
282
THE
EPR
EFFECT
283
TARGETING
STRATEGIES:
TRANSPORTERS
284
TARGETING
STRATEGIES:
ENZYME
ACTIVATION
286
OTHER
TARGETING
STRATEGIES
287
CONCLUSIONS
288
REFERENCES
289
12
FORMULATION
OF
PEPTIDES
FOR
TARGETED
DELIVERY
299
PANKTI
GANATRA,
KAREN
SAISWANI,
NIKITA
NAIR,
AVINASH
GUNJAL,
RATNESH
JAIN,
AND
PRAJAKTA
DANDEKAR
12.1
12.2
12.2.1
12.2.2
12.2.3
12.2.4
12.2.5
12.2.6
12.3
INTRODUCTION
299
PEPTIDES
USED
IN
CANCER
THERAPY
302
LUNG
CANCER
303
MELANOMA
304
PANCREATIC
CANCER
306
BRAIN
CANCER
307
BREAST
CANCER
309
LEUKEMIA
312
PEPTIDE-TARGETING
BASED
ON
SITE
OF
ACTION
315
CONTENTS
XI
12.3.1
12.3.2
12.3.3
12.3.4
12.4
TOPICAL
DELIVERY
OF
PEPTIDES
315
OCULAR
DELIVERY
OF
PEPTIDES
31
7
BRAIN
DELIVERY
OF
PEPTIDES
319
LUNG-TARGETED
DELIVERY
OF
PEPTIDES
321
CONCLUSION
AND
FUTURE
PROSPECTS
323
REFERENCES
324
13
ANTIBODY-BASED
TARGETED
T-CELL
THERAPIES
327
MANOJ
BANSODE,
KAUSHIK
DEB,
AND
SARMISTHA
DEB
13.1
13.2
13.3
13.4
13.5
13.6
13.7
13.8
13.9
13.10
13.11
13.12
13.13
13.14
13.15
INTRODUCTION
327
IMMUNE-DIRECTED CANCER
CELL
DEATH
328
IMMUNOTHERAPY
STRATEGIES
IN
CANCER
328
T-CELL
THERAPY
329
NATURALLY
OCCURRING
T
CELLS
329
GENETICALLY
MODIFIED
OCCURRING
T
CELLS
330
CLINICAL
IMPLICATION OF
T-CELL
AND
CAR-T-CELL
THERAPY:
330
ANTIBODY-INDUCED
T-CELL
THERAPY
332
A
BISPECIFIC
ANTIBODY
(BSABS)-INDUCED
T-CELL
THERAPY
332
FORMATS
OF
BSABS
335
TRIOMAB
ANTIBODIES
IN
T-CELL
THERAPY
335
BISPECIFIC
ANTIBODIES
IN
T-CELL
THERAPY
336
CLINICALLY
APPROVED
T-CELL-ACTIVATING
ANTIBODIES
337
PROSPECTS
337
CONCLUSION
339
REFERENCES
339
14
DEVICES
FOR
ACTIVE
TARGETED
DELIVERY:
A
WAY
TO
CONTROL
THE
RATE
AND
EXTENT
OF
DRUG
ADMINISTRATION
349
JONATHAN
FARO
BARROS,
PHEDRA
F.
SAHRAOUI,
YOGESHVOR
N.
KALIA,
AND
MARIA
LAPTEVA
14.1
14.2
14.2.1
14.2.2
14.2.3
14.2.4
14.2.4.1
14.2.4.2
14.2.4.3
14.3
14.3.1
14.3.1.1
14.3.1.2
14.3.1.3
14.3.2
INTRODUCTION
349
MACROFABRICATED
DEVICES
-
DRUG
INFUSION
PUMPS
351
PERISTALTIC
PUMPS
351
GAS-DRIVEN
PUMPS
352
OSMOTIC
PUMPS
353
INSULIN
PUMPS
354
DIABETES
AND
INSULIN
PRODUCT
DEVELOPMENT
354
OPEN-LOOP
INSULIN
DELIVERY
SYSTEMS
355
CLOSED-LOOP
INSULIN
DELIVERY
SYSTEMS
360
MICROFABRICATED
AND
NANOFABRICATED
DRUG
DELIVERY
DEVICES
364
MICROELECTROMECHANICAL
SYSTEMS
(MEMS)
364
MICROCHIP-BASED
MEMS
364
PUMP-BASED
MEMS
366
MEMS
-
EFFORTS
TO
CLOSE
THE
LOOP
368
NANOFABRICATED
DRUG
DELIVERY
DEVICES
369
XII
I
CONTENTS
INDEX
425
14.4
14.5
NONINVASIVE
ACTIVE
DRUG
DELIVERY
SYSTEMS:
IONTOPHORESIS
372
CONCLUSIONS
376
ACKNOWLEDGMENTS
377
LIST
OF
ABBREVIATIONS
377
REFERENCES
378
15
DRUG
DELIVERY
TO
THE
BRAIN:
TARGETING
TECHNOLOGIES
TO
DELIVER
THERAPEUTICS
TO
BRAIN
LESIONS
389
NISHIT
PATHAK,
SUNIL
K.
VIMAL,
CAO
HONGYI,
AND
SANJIB
BHATTACHARYA
15.1
15.2
15.2.1
15.2.2
15.3
15.3.1
15.3.1.1
15.3.2
15.3.2.1
15.3.3
15.3.3.1
15.3.4
15.3.4.1
15.3.4.2
15.3.5
15.4
15.4.1
15.4.2
15.4.3
15.4.4
15.4.5
15.5
15.6
INTRODUCTION
389
BRAIN
TUMOR
390
OBSTACLES
TO
BRAIN
TUMOR-TARGETED
DELIVERY
391
BRAIN-TUMOR-FOCUSED
NANO-DRUG
DELIVERY
393
NEURODEGENERATIVE
DISEASES
396
ALZHEIMER
'
S
DISEASE
(AD)
396
ALZHEIMER
'
S
DISEASE
FOCUSED
ON
DRUG
DELIVERY
396
PARKINSON
'
S
DISEASE
399
DRUG
DELIVERY
FOCUSSED
ON
PARKINSON
'
S
DRUG
DISEASE
399
CEREBROVASCULAR
DISEASE
400
DRUG
DELIVERY
FOR
CEREBROVASCULAR
DISEASE
400
INFLAMMATORY
DISEASES
(ID)
402
INFLAMMATORY
DISEASES (ID)
FOCUSED
ON
DRUG
DELIVERY
402
DRUG
DELIVERY
FOR
THE
TREATMENT
OF
NEURO-AIDS
403
DRUG
DELIVERY
FOR
MULTIPLE
SCLEROSIS
(MS)
403
DRUG
DELIVERY
FOR
CNS
DISORDERS
404
TAU
THERAPY
405
IMMUNOTHERAPY
407
GENE
IMMUNOTHERAPY
(GIT)
407
CHEMOTHERAPY
(CT)
408
PHOTOIMMUNOTHERAPY
(PIT)
408
FUTURE
PROSPECTS
410
CONCLUSIONS
410
LIST
OF
ABBREVIATIONS
411
REFERENCES
412 |
| any_adam_object | 1 |
| any_adam_object_boolean | 1 |
| author2 | Bachhav, Yogeshwar G. |
| author2_role | edt |
| author2_variant | y g b yg ygb |
| author_GND | (DE-588)1198937505 |
| author_facet | Bachhav, Yogeshwar G. |
| building | Verbundindex |
| bvnumber | BV048641353 |
| classification_rvk | VX 8560 |
| ctrlnum | (OCoLC)1357148901 (DE-599)DNB1255089520 |
| discipline | Chemie / Pharmazie |
| discipline_str_mv | Chemie / Pharmazie |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02820nam a2200709 cb4500</leader><controlfield tag="001">BV048641353</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20240311 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">230110s2023 gw a||| |||| 00||| eng d</controlfield><datafield tag="015" ind1=" " ind2=" "><subfield code="a">22,N15</subfield><subfield code="2">dnb</subfield></datafield><datafield tag="016" ind1="7" ind2=" "><subfield code="a">1255089520</subfield><subfield code="2">DE-101</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9783527347810</subfield><subfield code="9">978-3-527-34781-0</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">352734781X</subfield><subfield code="9">3-527-34781-X</subfield></datafield><datafield tag="024" ind1="3" ind2=" "><subfield code="a">9783527347810</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1357148901</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DNB1255089520</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="044" ind1=" " ind2=" "><subfield code="a">gw</subfield><subfield code="c">XA-DE-BW</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-29T</subfield><subfield code="a">DE-19</subfield><subfield code="a">DE-703</subfield><subfield code="a">DE-11</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">VX 8560</subfield><subfield code="0">(DE-625)147831:253</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="8">1\p</subfield><subfield code="a">540</subfield><subfield code="2">23sdnb</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Targeted drug delivery</subfield><subfield code="c">edited by Yogeshwar Bachhav</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Weinheim</subfield><subfield code="b">Wiley-VCH</subfield><subfield code="c">[2023]</subfield></datafield><datafield tag="264" ind1=" " ind2="4"><subfield code="c">© 2023</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">xvii, 438 Seiten</subfield><subfield code="b">Illustrationen, Diagramme</subfield><subfield code="c">24.4 cm x 17 cm</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Methods and principles in medicinal chemistry</subfield><subfield code="v">Volume 82</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Targeted drug delivery</subfield><subfield code="0">(DE-588)4302415-4</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">CH62: Wirkstoffformulierung, Wirkstofftransport</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Chemie</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Chemistry</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Drug Formulation & Delivery</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">MDM0: Pharmakologie u. Pharmazeutische Medizin</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Medical Science</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Medizin</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">NT40: Nanomedizin</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Nanomedicine</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Nanomedizin</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Nanotechnologie</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Nanotechnology</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Pharmacology & Pharmaceutical Medicine</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Pharmakologie</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Pharmakologie u. Pharmazeutische Medizin</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Wirkstoffformulierung, Wirkstofftransport</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Wirkstofffreisetzung</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)4143413-4</subfield><subfield code="a">Aufsatzsammlung</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Targeted drug delivery</subfield><subfield code="0">(DE-588)4302415-4</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bachhav, Yogeshwar G.</subfield><subfield code="0">(DE-588)1198937505</subfield><subfield code="4">edt</subfield></datafield><datafield tag="710" ind1="2" ind2=" "><subfield code="a">Wiley-VCH</subfield><subfield code="0">(DE-588)16179388-5</subfield><subfield code="4">pbl</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Online-Ausgabe, PDF</subfield><subfield code="z">978-3-527-82786-2</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Online-Ausgabe, EPUB</subfield><subfield code="z">978-3-527-82787-9</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Online-Ausgabe, oBook</subfield><subfield code="z">978-3-527-82785-5</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">Methods and principles in medicinal chemistry</subfield><subfield code="v">Volume 82</subfield><subfield code="w">(DE-604)BV035418617</subfield><subfield code="9">82</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">X:MVB</subfield><subfield code="u">http://www.wiley-vch.de/publish/dt/books/ISBN978-3-527-34781-0/</subfield><subfield code="3">Kurzbeschreibung</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">DNB Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=034016275&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-034016275</subfield></datafield><datafield tag="883" ind1="1" ind2=" "><subfield code="8">1\p</subfield><subfield code="a">vlb</subfield><subfield code="d">20220408</subfield><subfield code="q">DE-101</subfield><subfield code="u">https://d-nb.info/provenance/plan#vlb</subfield></datafield></record></collection> |
| genre | (DE-588)4143413-4 Aufsatzsammlung gnd-content |
| genre_facet | Aufsatzsammlung |
| id | DE-604.BV048641353 |
| illustrated | Illustrated |
| index_date | 2024-07-03T21:17:41Z |
| indexdate | 2024-07-10T09:44:50Z |
| institution | BVB |
| institution_GND | (DE-588)16179388-5 |
| isbn | 9783527347810 352734781X |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-034016275 |
| oclc_num | 1357148901 |
| open_access_boolean | |
| owner | DE-29T DE-19 DE-BY-UBM DE-703 DE-11 |
| owner_facet | DE-29T DE-19 DE-BY-UBM DE-703 DE-11 |
| physical | xvii, 438 Seiten Illustrationen, Diagramme 24.4 cm x 17 cm |
| publishDate | 2023 |
| publishDateSearch | 2023 |
| publishDateSort | 2023 |
| publisher | Wiley-VCH |
| record_format | marc |
| series | Methods and principles in medicinal chemistry |
| series2 | Methods and principles in medicinal chemistry |
| spelling | Targeted drug delivery edited by Yogeshwar Bachhav Weinheim Wiley-VCH [2023] © 2023 xvii, 438 Seiten Illustrationen, Diagramme 24.4 cm x 17 cm txt rdacontent n rdamedia nc rdacarrier Methods and principles in medicinal chemistry Volume 82 Targeted drug delivery (DE-588)4302415-4 gnd rswk-swf CH62: Wirkstoffformulierung, Wirkstofftransport Chemie Chemistry Drug Formulation & Delivery MDM0: Pharmakologie u. Pharmazeutische Medizin Medical Science Medizin NT40: Nanomedizin Nanomedicine Nanomedizin Nanotechnologie Nanotechnology Pharmacology & Pharmaceutical Medicine Pharmakologie Pharmakologie u. Pharmazeutische Medizin Wirkstoffformulierung, Wirkstofftransport Wirkstofffreisetzung (DE-588)4143413-4 Aufsatzsammlung gnd-content Targeted drug delivery (DE-588)4302415-4 s DE-604 Bachhav, Yogeshwar G. (DE-588)1198937505 edt Wiley-VCH (DE-588)16179388-5 pbl Erscheint auch als Online-Ausgabe, PDF 978-3-527-82786-2 Erscheint auch als Online-Ausgabe, EPUB 978-3-527-82787-9 Erscheint auch als Online-Ausgabe, oBook 978-3-527-82785-5 Methods and principles in medicinal chemistry Volume 82 (DE-604)BV035418617 82 X:MVB http://www.wiley-vch.de/publish/dt/books/ISBN978-3-527-34781-0/ Kurzbeschreibung DNB Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=034016275&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis 1\p vlb 20220408 DE-101 https://d-nb.info/provenance/plan#vlb |
| spellingShingle | Targeted drug delivery Methods and principles in medicinal chemistry Targeted drug delivery (DE-588)4302415-4 gnd |
| subject_GND | (DE-588)4302415-4 (DE-588)4143413-4 |
| title | Targeted drug delivery |
| title_auth | Targeted drug delivery |
| title_exact_search | Targeted drug delivery |
| title_exact_search_txtP | Targeted drug delivery |
| title_full | Targeted drug delivery edited by Yogeshwar Bachhav |
| title_fullStr | Targeted drug delivery edited by Yogeshwar Bachhav |
| title_full_unstemmed | Targeted drug delivery edited by Yogeshwar Bachhav |
| title_short | Targeted drug delivery |
| title_sort | targeted drug delivery |
| topic | Targeted drug delivery (DE-588)4302415-4 gnd |
| topic_facet | Targeted drug delivery Aufsatzsammlung |
| url | http://www.wiley-vch.de/publish/dt/books/ISBN978-3-527-34781-0/ http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=034016275&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| volume_link | (DE-604)BV035418617 |
| work_keys_str_mv | AT bachhavyogeshwarg targeteddrugdelivery AT wileyvch targeteddrugdelivery |